MiMark diagnostics
MiMark diagnostics is a company.
Active
Updated: ·
Financial History
Total Raised
N/A
Valuation
N/A
Leadership Team
Key people at MiMark diagnostics.
MiMark diagnostics is a company.
Key people at MiMark diagnostics.
Key people at MiMark diagnostics.
MiMARK Diagnostics is a Spanish femtech startup and spin-off from the Vall d'Hebron Institute of Research (VHIR), founded in 2021 to reshape gynecological diagnostics through innovative in vitro diagnostic (IVD) assays using gynecological fluids as a novel liquid biopsy.[1][5] The company develops a pipeline of tests starting with WomEC, a non-invasive immunoassay for endometrial cancer detection via protein biomarkers in uterine fluids, achieving 99% sensitivity and 87% specificity to rule out the disease and reduce unnecessary invasive biopsies like hysteroscopies.[2][3][4] Targeting women with gynecological symptoms, MiMARK serves clinicians and healthcare systems by improving diagnostic accuracy, speed, patient comfort, and resource efficiency, while expanding into endometriosis and ovarian cancer.[1][2] With over €3M in initial private capital plus grants like the EIT Health Wild Card (€1.5M) and EIC Accelerator (€2.5M), and a €4.22M seed round in 2024 from investors including Clave Capital, Inveready, and others, MiMARK shows strong growth momentum as its lead product advances to verification and validation stages.[1][4]
MiMARK emerged as a VHIR spin-off in 2021, led by a diverse founding team of scientists, clinicians, and innovators with deep expertise in gynecology and diagnostics, including CEO and co-founder Marina Rigau and co-founder Eva Colás Ortega.[1][3][4] The idea stemmed from research verifying protein biomarkers in uterine aspirate samples via mass spectrometry and ELISA, backed by eight retrospective studies on nearly 1,000 patients and international publications like a 2016 Oncotarget paper on LC-PRM workflows.[5] Early traction included the EIT Health Wild Card 2020 award (€1.5M), securing two EU patents, and 2022 recognitions such as the STEM Women Congress Award and Women Startup Awards, culminating in the 2024 GSK e-llas Innovation Hub win and €4.22M seed round to propel WomEC toward market.[4][5]
MiMARK rides the femtech and precision diagnostics wave, leveraging liquid biopsy innovations—proven in oncology—to gynecological cancers, where traditional methods like biopsies lag in accuracy and patient experience.[1][3] Timing aligns with rising women's health investments and EU grants prioritizing preventative care, as endometrial cancer rates climb amid aging populations and post-menopausal risks.[3][4] Market forces favor it: high unmet needs in under-researched gynecological diseases hinder pharma trials, while MiMARK's tools enable better patient stratification and resource optimization.[2] By shifting to non-invasive, evidence-based diagnostics, it influences the ecosystem toward patient-centric models, supported by EIT Health's push for efficient healthcare delivery.[3]
MiMARK is poised to launch WomEC commercially post-validation, scaling its pipeline with €4.22M seed fueling EU market entry and global expansion via patents and partnerships.[4][5] Trends like AI-enhanced biomarkers, femtech funding surges, and regulatory fast-tracks for women's health will accelerate growth, potentially disrupting diagnostics for millions.[1][2] Its influence may evolve from niche innovator to ecosystem leader, partnering with pharma for trials and hospitals for adoption, ultimately reducing invasive procedures and transforming gynecological care worldwide—validating its mission to reshape women's health from the ground up.[3][4]
